Shin Min Kyung, Shin Sangjin, Lee Ja Youn, Koh Youngil
National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Blood Res. 2017 Mar;52(1):31-36. doi: 10.5045/br.2017.52.1.31. Epub 2017 Mar 27.
A number of alternative donor options exist for patients who fail to find domestic HLA-matched donors for allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed physicians' perspectives on allo-HSCT donor selection when a matched domestic donor is not available.
We administered a questionnaire survey to 55 hematologists (response rate: 28%) who attended the annual spring conference of the Korean Society of Haematology in 2015. The questionnaire contained four clinical allo-HSCT scenarios and the respondents were asked to choose the most preferred donor among the given options.
In all four scenarios, the hematologists preferred a matched international donor over partially mismatched unrelated domestic or haplo-matched family donors. The numbers of hematologists who chose a matched international donor (HLA 8/8) in cases of acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, and aplastic anemia were 37 (67.3%), 41 (74.6%), 33 (60.0%), and 36 (65.5%), respectively. The important factors that affected donor selection included "expecting better clinical outcomes (40.5%)" and "lower risk of side effects (23.4%)." The majority of participants (80%) responded that allo-HSCT guidelines for donor selection customized for the Korean setting are necessary.
Although hematologists still prefer perfectly matched foreign donors when a fully matched domestic allo-HSCT donor is not available, we confirmed that there was variation in their responses. For evidence-based clinical practice, it is necessary to provide further comparative clinical evidence on allo-HSCT from haplo-matched family donors and fully matched unrelated international donors.
对于在同种异体造血干细胞移植(allo-HSCT)中未能找到国内HLA匹配供者的患者,存在多种替代供者选择。我们评估了在没有匹配的国内供者时,医生对于allo-HSCT供者选择的观点。
我们对参加2015年韩国血液学会年度春季会议的55名血液科医生进行了问卷调查(回复率:28%)。问卷包含四个临床allo-HSCT场景,要求受访者在给定选项中选择最偏好的供者。
在所有四个场景中,血液科医生更倾向于选择匹配的国际供者,而非部分不匹配的无关国内供者或单倍型匹配的家族供者。在急性髓系白血病、慢性髓系白血病、急性淋巴细胞白血病和再生障碍性贫血病例中,选择匹配的国际供者(HLA 8/8)的血液科医生人数分别为37名(67.3%)、41名(74.6%)、33名(60.0%)和36名(65.5%)。影响供者选择的重要因素包括“期望更好的临床结果(40.5%)”和“副作用风险更低(23.4%)”。大多数参与者(80%)回答说需要针对韩国情况定制的allo-HSCT供者选择指南。
尽管在没有完全匹配的国内allo-HSCT供者时,血液科医生仍然更倾向于完全匹配的国外供者,但我们证实他们的回答存在差异。为了基于证据的临床实践,有必要提供关于单倍型匹配的家族供者和完全匹配的无关国际供者的allo-HSCT的进一步比较临床证据。